Global Retinal Biologics Market Size Study & Forecast, by Drug Class (VEGF-A Antagonist, TNF-a Inhibitor), by Disease Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Other Disease Indications), and Regional Analysis, 2023-2030

Global Retinal Biologics Market Size Study & Forecast, by Drug Class (VEGF-A Antagonist, TNF-a Inhibitor), by Disease Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Other Disease Indications), and Regional Analysis, 2023-2030

Global Retinal Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.8% during the forecast period 2023-2030. Retinal biologics are specialized treatments for retinal diseases that employ biological substances such as proteins, antibodies, gene therapy, or cell-based therapies. These innovative therapies target specific pathways involved in conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion Derived from living organisms such as proteins or antibodies, these biologics are meticulously designed to target precise molecules or processes implicated in retinal diseases. By homing in on the underlying mechanisms, they offer targeted therapies that surpass conventional approaches in efficacy. Administered primarily through intravitreal injections, the delivery method ensures direct application of the medication into the eye, optimizing treatment precision and efficacy. The Retinal Biologics Market is expanding because of factors such as the rising number of FDA approvals, increasing healthcare expenditure, coupled with the growing aging population. The Retinal Biologics Market is poised for growth due to the introduction of diverse drug products aimed at treating retinal diseases, which is fostering increased competition in the market.

In addition, the prevalence of vision impairments, including diabetic retinopathy is to further stimulate market demand across the globe. According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion individuals globally are affected by either distant or near vision impairments, underscoring the urgent need for effective treatments in the retinal biologics market. Also, according to the study conducted by National Institute of Health (NIH) titled ""Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis,"" published in November 2021, the global prevalence of diabetic retinopathy among adults stood at an estimated 103.12 million in 2020. Projections suggest that by 2045, this figure rise substantially to reach 160.50 million individuals. This escalation in the prevalence of retinal diseases or diabetic retinopathy is anticipated to fuel demand for biological treatments, consequently propelling the growth of the Retinal Biologics Market during the estimated period of 2023-2030. Moreover, the rising innovation in biotechnology and drug development, as well as the growing investment in research and development present various lucrative opportunities over the forecast years. However, the high initial capital investment and stringent regulatory process are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Retinal Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing R&D activities and the growing number of FDA approvals. The market in this region is expected to witness further growth, supported by the presence of major players. Moreover, key stakeholders in the region are implementing various strategies such as acquisitions, product launches, and partnerships to fortify their positions. For instance, in June 2020, Novartis announced the U.S. FDA's approval for a label update for Beovu, which includes the addition of a subsection dedicated to retinal vasculitis or retinal vascular occlusion under 'Warnings and Precautions'. Similarly in September 2021, the U.S. FDA approved the first biosimilar, Byooviz, for the treatment of macular degeneration disease. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing prevalence of retinal diseases, the growing burden of the diabetic population, as well as advancements in biotechnology and drug development, are significantly propelling the market demand across the region.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals Inc.
AbbVie Inc.
MeiraGTx Limited
Oxurion NV
Novartis AG
GenSight Biologics S.A.
Adverum Biotechnologies Inc
SemaThera Inc.
Amgen Inc.

Recent Developments in the Market:
 In August 2023, Regeneron Pharmaceuticals, Inc. received approval from the U.S. FDA for an EYLEA HD injection. This approval encompasses its application in treating conditions such as diabetic retinopathy, wet age-related macular degeneration, and diabetic macular edema.
 In March 2023, Praetego Inc. secured funding of USD 300 million from the National Eye Institute. This financial support aims to propel the development of pioneering oral medications designed specifically for diabetic retinopathy.
 In April 2022, Shilpa Biologicals (SBPL) obtained a No Objection Certificate (NoC) from RCGM, Department of Biotechnology, enabling it to approach the Drugs Controller General of India (DCGI) to conduct clinical studies for its Biosimilar Aflibercept. This initiative targets the markets for Wet Age-Related Macular Degeneration (wAMD), Diabetic Retinopathy, Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion, both in India and globally.

Global Retinal Biologics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Drug Class, Disease Indication, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
VEGF-A Antagonist
TNF-a Inhibitor

By Disease Indication:
Macular Degeneration
Diabetic Retinopathy
Uveitis
Other Disease Indications

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd
Regeneron Pharmaceuticals Inc.
AbbVie Inc.
MeiraGTx Limited
Oxurion NV
Novartis AG
GenSight Biologics S.A.
Adverum Biotechnologies Inc
SemaThera Inc.
Amgen Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.